Skip to main content
OpenTrials
Completed

NCT Number: NCT02984215

aCGH Impacts Survival in Plasma Cell PTLD

Plasma-cell post-transplantation lymphoproliferative disorders (PC-PTLD) are rare monomorphic PTLD divided into plasma cell myeloma (PCM) and plasmacytoma-like lesion (PLL) PTLD. To date, there is no exhaustive published cytogenetic data on PC-PTLD. The investigators report array-based comparative genomic hybridization (aCGH) of 10 cases of PCM and PLL-PTLD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Post-transplantation Lymphoproliferative Disorders

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre hospitalier Lyon sud

Pierre-Bénite, Auvergne-Rhône-Alpes, 69126, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • WHO classification 2008 as monomorphic PCM (plasma cell myeloma) or PLL (plasmacytoma like lesion) / PTLD (post transplantation lymphoproliferative disorders).

Exclusion criteria

  • Other than PCM or PLL PTLD at diagnosis

Treatment and study plan

Primary outcomes

  1. Genome wide array-based comparative genomic hybridization (aCGH)

    Time frame: At diagnosis of PTLD, Day 0.

Secondary outcomes

  1. Overall survival according to aCGH complexity

    Time frame: Overall survival (OS) was calculated from date of diagnosis to date of death from any cause, up to 130 months.

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Official study title

Array-CGH in Plasma Cell Post-transplantation Lymphoproliferative Disorders

Important dates

Study start
1990
Primary completion
2012
Study completion
2016
First posted
Dec 6, 2016
Registry last updated
Dec 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.